论文部分内容阅读
HMG-CoA还原酶抑制剂为一类有前途的降胆固醇新药,初步研究表明,它能增加低密度脂蛋白(LDL)受体的活性,使冠心病的发生率明显减少。本品用药量小。除偶见横纹肌损害外,没有严重的副作用。但尚需在大量病人中进行长期观察。
HMG-CoA reductase inhibitor is a promising new cholesterol-lowering drug. Preliminary studies have shown that it can increase the activity of low-density lipoprotein (LDL) receptor and significantly reduce the incidence of coronary heart disease. This product is a small amount of medication. In addition to occasionally striated muscle damage, there are no serious side effects. However, long-term observation is still required in a large number of patients.